Statins in chronic kidney disease and kidney transplantation

Pharmacological Research

Volumn 88, Issue , 2014, Pages 62-73

  Kassimatis, Theodoros I ^a   Goldsmith, David J A ^b  

^a IASO GENERAL HOSPITAL   (Greece)

^b GUY S HOSPITAL   (United Kingdom)

Author keywords

Cardiovascular outcomes; Chronic kidney disease; HMG CoA reductase inhibitors; Kidney transplantation; Renal outcomes; Statins

Indexed keywords

ATORVASTATIN; CYCLOSPORIN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; EZETIMIBE; FLUINDOSTATIN; GEMFIBROZIL; GERANYLGERANYL PYROPHOSPHATE; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MACROLIDE; MONOCYTE CHEMOTACTIC PROTEIN 1; MYELOPEROXIDASE; OXIDIZED LOW DENSITY LIPOPROTEIN; PITAVASTATIN; PLACEBO; PRAVASTATIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1; VERAPAMIL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

AGING; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CREATININE CLEARANCE; DIABETES MELLITUS; DISEASE COURSE; DRUG METABOLISM; DYSLIPIDEMIA; GLOMERULUS FILTRATION RATE; HEART LEFT VENTRICLE HYPERTROPHY; HEMODIALYSIS PATIENT; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTENSION; IMMUNE RESPONSE; IMMUNOMODULATION; KIDNEY FAILURE; KIDNEY INJURY; KIDNEY TRANSPLANTATION; LIPOPROTEIN METABOLISM; LIVER METABOLISM; LIVER TOXICITY; LOW DRUG DOSE; MORTALITY; MUSCLE DISEASE; MYALGIA; MYOPATHY; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PLEIOTROPY; PODOCYTE; PRIORITY JOURNAL; PROTEIN PROCESSING; RENAL PROTECTION; REVIEW; RHABDOMYOLYSIS; SMOKING; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION INHIBITION; DYSLIPIDEMIAS; METABOLISM; RENAL INSUFFICIENCY, CHRONIC;

DYSLIPIDEMIAS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; KIDNEY TRANSPLANTATION; RENAL INSUFFICIENCY, CHRONIC;

EID: 84906789720     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2014.06.011     Document Type: Review

References (170)

1. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial Lancet 360 July (9326) 2002 7 22 PubMed PMID: 12114036
2. P.S. Sever, B. Dahlof, N.R. Poulter, H. Wedel, G. Beevers, and M. Caulfield et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial Drugs 64 Suppl. 2 2004 43 60 PubMed PMID: 15765890 (Pubitemid 39657106)
3. K.I. Paraskevas, A.A. Tzovaras, D.D. Briana, and D.P. Mikhailidis Emerging indications for statins: a pluripotent family of agents with several potential applications Curr Pharm Des 13 35 2007 3622 3636 PubMed PMID: 18220799 (Pubitemid 350238933)
4. M.J. Sarnak, A.S. Levey, A.C. Schoolwerth, J. Coresh, B. Culleton, and L.L. Hamm et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention Hypertension 42 November (5) 2003 1050 1065 PubMed PMID: 14604997 (Pubitemid 37413751)
5. G. Manjunath, H. Tighiouart, J. Coresh, B. Macleod, D.N. Salem, and J.L. Griffith et al. Level of kidney function as a risk factor for cardiovascular outcomes in the elderly Kidney Int 63 March (3) 2003 1121 1129 PubMed PMID: 12631096 (Pubitemid 36315592)
6. A.S. Levey, P.E. de Jong, J. Coresh, M. El Nahas, B.C. Astor, and K. Matsushita et al. The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report Kidney Int 80 July (1) 2011 17 28 PubMed PMID: 21150873 [Epub 2010/12/15]
7. P.O. Attman, and P. Alaupovic Lipid abnormalities in chronic renal insufficiency Kidney Int 31 April (Suppl.) 1991 S16 S23 PubMed PMID: 2046265
8. E.L. Schiffrin, M.L. Lipman, and J.F. Mann Chronic kidney disease: effects on the cardiovascular system Circulation 116 July (1) 2007 85 97 PubMed PMID: 17606856 [Epub 2007/07/04] (Pubitemid 47016250)
9. G.M. London, and P.S. Parfrey Cardiac disease in chronic uremia: pathogenesis Adv Ren Replace Ther 4 July (3) 1997 194 211 PubMed PMID: 9239425 [Epub 1997/07/01] (Pubitemid 27304995)
10. V.M. Campese, and J. Park HMG-CoA reductase inhibitors and the kidney Kidney Int 71 June (12) 2007 1215 1222 PubMed PMID: 17495867 (Pubitemid 46884244)
11. H.H. Parving, U.M. Smidt, B. Friisberg, V. Bonnevie-Nielsen, and A.R. Andersen A prospective study of glomerular filtration rate and arterial blood pressure in insulin-dependent diabetics with diabetic nephropathy Diabetologia 20 April (4) 1981 457 461 PubMed PMID: 7016639 [Epub 1981/04/01] (Pubitemid 11098915)
12. G.C. Viberti, R.W. Bilous, D. Mackintosh, and H. Keen Monitoring glomerular function in diabetic nephropathy. A prospective study Am J Med 74 February (2) 1983 256 264 PubMed PMID: 6401924 [Epub 1983/02/01] (Pubitemid 13192182)
13. C.K. Abrass Cellular lipid metabolism and the role of lipids in progressive renal disease Am J Nephrol 24 January-February (1) 2004 46 53 PubMed PMID: 14707435 [Epub 2004/01/07] (Pubitemid 38258276)
14. A. Chait, and J.W. Heinecke Lipoprotein modification: cellular mechanisms Curr Opin Lipidol 5 October (5) 1994 365 370 PubMed PMID: 7858911 [Epub 1994/10/01] (Pubitemid 24341346)
15. H.J. Grone, A. Walli, E. Grone, P. Niedmann, J. Thiery, and D. Seidel et al. Induction of glomerulosclerosis by dietary lipids. A functional and morphologic study in the rat Lab Invest 60 March (3) 1989 433 446 PubMed PMID: 2927082 [Epub 1989/03/01] (Pubitemid 19095960)
16. H.C. Rayner, V.L. Ross-Gilbertson, and J. Walls The role of lipids in the pathogenesis of glomerulosclerosis in the rat following subtotal nephrectomy Eur J Clin Invest 20 February (1) 1990 97 104 PubMed PMID: 2108041 [Epub 1990/02/01] (Pubitemid 20056280)
17. M.P. O'Donnell, B.L. Kasiske, S.A. Katz, P.G. Schmitz, and W.F. Keane Lovastatin but not enalapril reduces glomerular injury in Dahl salt-sensitive rats Hypertension 20 November (5) 1992 651 658 PubMed PMID: 1428116 [Epub 1992/11/01]
18. R. Rubin, S. Silbiger, L. Sablay, and J. Neugarten Combined antihypertensive and lipid-lowering therapy in experimental glomerulonephritis Hypertension 23 January (1) 1994 92 95 PubMed PMID: 8282335 [Epub 1994/01/01] (Pubitemid 24022049)
19. T.I. Kassimatis, and P.A. Konstantinopoulos The role of statins in chronic kidney disease (CKD): friend or foe? Pharmacol Ther 122 June (3) 2009 312 323 PubMed PMID: 19351546 [Epub 2009/04/09]
20. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification Am J Kidney Dis 39 February (2 Suppl. 1) 2002 S1 S266 PubMed PMID: 11904577
21. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease Kidney Int 3 Suppl. 2013 1 150
22. T. Kassimatis, and D. Goldsmith CVD in CKD: focus on the dyslipidemia problem A. Covic, M. Kanbay, E. Lerma, Dyslipidemias in kidney disease 2014 Springer New York 67 91
23. N.D. Vaziri, and H. Moradi Mechanisms of dyslipidemia of chronic renal failure Hemodial Int 10 January (1) 2006 1 7 PubMed PMID: 16441821 (Pubitemid 43263285)
24. G.A. Kaysen, J. Gambertoglio, J. Felts, and F.N. Hutchison Albumin synthesis, albuminuria and hyperlipemia in nephrotic patients Kidney Int 31 June (6) 1987 1368 1376 PubMed PMID: 3613408 (Pubitemid 17090501)
25. P.O. Attman, O. Samuelsson, A.C. Johansson, J.B. Moberly, and P. Alaupovic Dialysis modalities and dyslipidemia Kidney Int 84 May (Suppl.) 2003 S110 S112 PubMed PMID: 12694322 [Epub 2003/04/16]
26. O. Heimburger, P. Stenvinkel, L. Berglund, A. Tranoeus, and B. Lindholm Increased plasma lipoprotein(a) in continuous ambulatory peritoneal dialysis is related to peritoneal transport of proteins and glucose Nephron 72 2 1996 135 144 PubMed PMID: 8684516 [Epub 1996/01/01] (Pubitemid 26035366)
27. D.C. Wheeler Abnormalities of lipoprotein metabolism in CAPD patients Kidney Int 56 November (Suppl.) 1996 S41 S46 PubMed PMID: 8914053 [Epub 1996/11/01]
28. N.D. Vaziri Dyslipidemia of chronic renal failure: the nature, mechanisms, and potential consequences Am J Physiol Renal Physiol 290 February (2) 2006 F262 F272 PubMed PMID: 16403839 [Epub 2006/01/13]
29. E. Ok, A.G. Basnakian, E.O. Apostolov, Y.M. Barri, and S.V. Shah Carbamylated low-density lipoprotein induces death of endothelial cells: a link to atherosclerosis in patients with kidney disease Kidney Int 68 July (1) 2005 173 178 PubMed PMID: 15954906 [Epub 2005/06/16] (Pubitemid 43181374)
30. I. Rajman, L. Harper, D. McPake, M.J. Kendall, and D.C. Wheeler Low-density lipoprotein subfraction profiles in chronic renal failure Nephrol Dial Transplant 13 September (9) 1998 2281 2287 PubMed PMID: 9761510 [Epub 1998/10/07] (Pubitemid 28416554)
31. J. de Graaf, H.L. Hak-Lemmers, M.P. Hectors, P.N. Demacker, J.C. Hendriks, and A.F. Stalenhoef Enhanced susceptibility to in vitro oxidation of the dense low density lipoprotein subfraction in healthy subjects Arterioscler Thromb 11 March-April (2) 1991 298 306 PubMed PMID: 1998647 [Epub 1991/03/01]
32. A.C. St-Pierre, B. Cantin, G.R. Dagenais, P. Mauriege, P.M. Bernard, and J.P. Despres et al. Low-density lipoprotein subfractions and the long-term risk of ischemic heart disease in men: 13-year follow-up data from the Quebec Cardiovascular Study Arterioscler Thromb Vasc Biol 25 March (3) 2005 553 559 PubMed PMID: 15618542 [Epub 2004/12/25] (Pubitemid 40315677)
33. M.A. Austin, M.C. King, K.M. Vranizan, and R.M. Krauss Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk Circulation 82 August (2) 1990 495 506 PubMed PMID: 2372896 [Epub 1990/08/01] (Pubitemid 20257828)
34. A. Clementi, J.C. Kim, M. Floris, D.N. Cruz, F. Garzotto, and M. Zanella et al. Statin therapy is associated with decreased small, dense low-density lipoprotein levels in patients undergoing peritoneal dialysis Contrib Nephrol 178 2012 111 115 PubMed PMID: 22652726 [Epub 2012/06/02]
35. S. Erqou, S. Kaptoge, P.L. Perry, E. Di Angelantonio, A. Thompson, and I.R. White et al. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality JAMA 302 July (4) 2009 412 423 PubMed PMID: 19622820 [Epub2009/07/23]
36. A. Bennet, E. Di Angelantonio, S. Erqou, G. Eiriksdottir, G. Sigurdsson, and M. Woodward et al. Lipoprotein(a) levels and risk of future coronary heart disease: large-scale prospective data Arch Intern Med 168 March (6) 2008 598 608 PubMed PMID: 18362252 [Epub 2008/03/26] (Pubitemid 351468395)
37. T. Ohira, P.J. Schreiner, J.D. Morrisett, L.E. Chambless, W.D. Rosamond, and A.R. Folsom Lipoprotein(a) and incident ischemic stroke: the Atherosclerosis Risk in Communities (ARIC) study Stroke 37 June (6) 2006 1407 1412 PubMed PMID: 16675734 [Epub 2006/05/06] (Pubitemid 44305717)
38. J.J. Genest Jr., S.S. Martin-Munley, J.R. McNamara, J.M. Ordovas, J. Jenner, and R.H. Myers et al. Familial lipoprotein disorders in patients with premature coronary artery disease Circulation 85 June (6) 1992 2025 2033 PubMed PMID: 1534286 [Epub 1992/06/11]
39. E. Steyrer, S. Durovic, S. Frank, W. Giessauf, A. Burger, and H. Dieplinger et al. The role of lecithin: cholesterol acyltransferase for lipoprotein (a) assembly. Structural integrity of low density lipoproteins is a prerequisite for Lp(a) formation in human plasma J Clin Invest 94 December (6) 1994 2330 2340 PubMed PMID: 7989589 [Epub 1994/12/01]
40. J. Loscalzo, M. Weinfeld, G.M. Fless, and A.M. Scanu Lipoprotein(a), fibrin binding, and plasminogen activation Arteriosclerosis 10 March-April (2) 1990 240 245 PubMed PMID: 2138452 [Epub 1990/03/01] (Pubitemid 20103586)
41. S. Tsimikas, E.S. Brilakis, E.R. Miller, J.P. McConnell, R.J. Lennon, and K.S. Kornman et al. Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease N Engl J Med 353 July (1) 2005 46 57 PubMed PMID: 16000355 [Epub 2005/07/08] (Pubitemid 41007806)
42. S. Takami, S. Yamashita, S. Kihara, M. Ishigami, K. Takemura, and N. Kume et al. Lipoprotein(a) enhances the expression of intercellular adhesion molecule-1 in cultured human umbilical vein endothelial cells Circulation 97 March (8) 1998 721 728 PubMed PMID: 9498534 [Epub 1998/03/14] (Pubitemid 28135333)
43. T.F. Zioncheck, L.M. Powell, G.C. Rice, D.L. Eaton, and R.M. Lawn Interaction of recombinant apolipoprotein(a) and lipoprotein(a) with macrophages J Clin Invest 87 March (3) 1991 767 771 PubMed PMID: 1825665 [Epub 1991/03/01]
44. M. Kuboyama, M. Ageta, T. Ishihara, Y. Fujiura, N. Kashio, and I. Ikushima Serum lipoprotein(a) concentration and Apo(a) isoform under the condition of renal dysfunction J Atheroscler Thromb 10 5 2003 283 289 PubMed PMID: 14718745 [Epub 2004/01/14]
45. M.D. Cressman, R.J. Heyka, E.P. Paganini, J. O'Neil, C.I. Skibinski, and H.F. Hoff Lipoprotein(a) is an independent risk factor for cardiovascular disease in hemodialysis patients Circulation 86 August (2) 1992 475 482 PubMed PMID: 1386292 [Epub 1992/08/01]
46. Y. Koda, S. Nishi, M. Suzuki, and Y. Hirasawa Lipoprotein(a) is a predictor for cardiovascular mortality of hemodialysis patients Kidney Int 71 July (Suppl.) 1999 S251 S253 PubMed PMID: 10412791 [Epub 1999/07/21]
47. M. Tonelli, N. Wiebe, B. Culleton, A. House, C. Rabbat, and M. Fok et al. Chronic kidney disease and mortality risk: a systematic review J Am Soc Nephrol 17 July (7) 2006 2034 2047 PubMed PMID: 16738019 (Pubitemid 44036188)
48. K. Matsushita, M. van der Velde, B.C. Astor, M. Woodward, A.S. Levey, and P.E. de Jong et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis Lancet 375 June (9731) 2010 2073 2081 PubMed PMID: 20483451 [Epub 2010/05/21]
49. A.S. Go, G.M. Chertow, D. Fan, C.E. McCulloch, and C.Y. Hsu Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization N Engl J Med 351 September (13) 2004 1296 1305 PubMed PMID: 15385656 [Epub 2004/09/24]
50. M. van der Velde, K. Matsushita, J. Coresh, B.C. Astor, M. Woodward, and A. Levey et al. Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts Kidney Int 79 June (12) 2011 1341 1352 PubMed PMID: 21307840 [Epub 2011/02/11]
51. F.C. Brosius 3rd, T.H. Hostetter, E. Kelepouris, M.M. Mitsnefes, S.M. Moe, and M.A. Moore et al. Detection of chronic kidney disease in patients with or at increased risk of cardiovascular disease: a science advisory from the American Heart Association Kidney And Cardiovascular Disease Council; the Councils on High Blood Pressure Research, Cardiovascular Disease in the Young, and Epidemiology and Prevention; and the Quality of Care and Outcomes Research Interdisciplinary Working Group: developed in collaboration with the National Kidney Foundation Circulation 114 September (10) 2006 1083 1087 PubMed PMID: 16894032 (Pubitemid 44358886)
52. A.S. Levey, J.A. Beto, B.E. Coronado, G. Eknoyan, R.N. Foley, and B.L. Kasiske et al. Controlling the epidemic of cardiovascular disease in chronic renal disease: what do we know? What do we need to learn? Where do we go from here? National Kidney Foundation Task Force on Cardiovascular Disease Am J Kidney Dis 32 November (5) 1998 853 906 PubMed PMID: 9820460 (Pubitemid 28516321)
53. P. Muntner, J. He, B.C. Astor, A.R. Folsom, and J. Coresh Traditional and nontraditional risk factors predict coronary heart disease in chronic kidney disease: results from the atherosclerosis risk in communities study J Am Soc Nephrol 16 February (2) 2005 529 538 PubMed PMID: 15625072 [Epub 2004/12/31] (Pubitemid 41725151)
54. M.R. Law, N.J. Wald, and S.G. Thompson By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? BMJ 308 February (6925) 1994 367 372 PubMed PMID: 8043072 (Pubitemid 24078498)
55. F.M. Sacks, M.A. Pfeffer, L.A. Moye, J.L. Rouleau, J.D. Rutherford, and T.G. Cole et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators N Engl J Med 335 October (14) 1996 1001 1009 PubMed PMID: 8801446 (Pubitemid 26338729)
56. J.E. Rossouw, B. Lewis, and B.M. Rifkind The value of lowering cholesterol after myocardial infarction N Engl J Med 323 October (16) 1990 1112 1119 PubMed PMID: 2215579 (Pubitemid 20370733)
57. J. Pekkanen, S. Linn, G. Heiss, C.M. Suchindran, A. Leon, and B.M. Rifkind et al. Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease N Engl J Med 322 June (24) 1990 1700 1707 PubMed PMID: 2342536 [Epub 1990/06/14] (Pubitemid 20231527)
58. Y. Liu, J. Coresh, J.A. Eustace, J.C. Longenecker, B. Jaar, and N.E. Fink et al. Association between cholesterol level and mortality in dialysis patients: role of inflammation and malnutrition JAMA 291 January (4) 2004 451 459 PubMed PMID: 14747502 (Pubitemid 38129749)
59. R.D. Kilpatrick, C.J. McAllister, C.P. Kovesdy, S.F. Derose, J.D. Kopple, and K. Kalantar-Zadeh Association between serum lipids and survival in hemodialysis patients and impact of race J Am Soc Nephrol 18 January (1) 2007 293 303 PubMed PMID: 17167113 [Epub 2006/12/15] (Pubitemid 46053442)
60. K. Iseki, M. Yamazato, M. Tozawa, and S. Takishita Hypocholesterolemia is a significant predictor of death in a cohort of chronic hemodialysis patients Kidney Int 61 May (5) 2002 1887 1893 PubMed PMID: 11967041 [Epub 2002/04/23] (Pubitemid 34437945)
61. V. Chawla, T. Greene, G.J. Beck, J.W. Kusek, A.J. Collins, and M.J. Sarnak et al. Hyperlipidemia and long-term outcomes in nondiabetic chronic kidney disease Clin J Am Soc Nephrol 5 September (9) 2010 1582 1587 PubMed PMID: 20558558 [Epub 2010/06/19]
62. K. Kalantar-Zadeh, G. Block, M.H. Humphreys, and J.D. Kopple Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients Kidney Int 63 March (3) 2003 793 808 PubMed PMID: 12631061 [Epub 2003/03/13] (Pubitemid 36315558)
63. G.A. Kaysen, and J.P. Eiserich The role of oxidative stress-altered lipoprotein structure and function and microinflammation on cardiovascular risk in patients with minor renal dysfunction J Am Soc Nephrol 15 March (3) 2004 538 548 PubMed PMID: 14978155 [Epub 2004/02/24] (Pubitemid 38294783)
64. D.E. Weiner, H. Tighiouart, E.F. Elsayed, J.L. Griffith, D.N. Salem, and A.S. Levey et al. The relationship between nontraditional risk factors and outcomes in individuals with stage 3 to 4 CKD Am J Kidney Dis 51 February (2) 2008 212 223 PubMed PMID: 18215699 [Epub 2008/01/25]
65. R.S. Parekh, L.C. Plantinga, W.H. Kao, L.A. Meoni, B.G. Jaar, and N.E. Fink et al. The association of sudden cardiac death with inflammation and other traditional risk factors Kidney Int 74 November (10) 2008 1335 1342 PubMed PMID: 18769368 [Epub 2008/09/05]
66. J. Kendrick, and M.B. Chonchol Nontraditional risk factors for cardiovascular disease in patients with chronic kidney disease Nat Clin Pract Nephrol 4 December (12) 2008 672 681 PubMed PMID: 18825155 [Epub 2008/10/01]
67. B. Canaud, J. Cristol, M. Morena, H. Leray-Moragues, J. Bosc, and F. Vaussenat Imbalance of oxidants and antioxidants in haemodialysis patients Blood Purif 17 2-3 1999 99 106 PubMed PMID: 10449867 [Epub 1999/08/18] (Pubitemid 29403567)
68. D.M. Small, J.S. Coombes, N. Bennett, D.W. Johnson, and G.C. Gobe Oxidative stress, anti-oxidant therapies and chronic kidney disease Nephrology (Carlton) 17 May (4) 2012 311 321 PubMed PMID: 22288610 [Epub 2012/02/01]
69. J. Himmelfarb, P. Stenvinkel, T.A. Ikizler, and R.M. Hakim The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia Kidney Int 62 November (5) 2002 1524 1538 PubMed PMID: 12371953 [Epub 2002/10/10] (Pubitemid 35286260)
70. N.D. Vaziri, M. Dicus, N.D. Ho, L. Boroujerdi-Rad, and R.K. Sindhu Oxidative stress and dysregulation of superoxide dismutase and NADPH oxidase in renal insufficiency Kidney Int 63 January (1) 2003 179 185 PubMed PMID: 12472781 [Epub 2002/12/11] (Pubitemid 35463919)
71. E. Maggi, R. Bellazzi, F. Falaschi, A. Frattoni, G. Perani, and G. Finardi et al. Enhanced LDL oxidation in uremic patients: an additional mechanism for accelerated atherosclerosis? Kidney Int 45 March (3) 1994 876 883 PubMed PMID: 8196291 [Epub 1994/03/01] (Pubitemid 24094502)
72. M. Rao, C. Wong, P. Kanetsky, M. Girndt, P. Stenvinkel, and M. Reilly et al. Cytokine gene polymorphism and progression of renal and cardiovascular diseases Kidney Int 72 September (5) 2007 549 556 PubMed PMID: 17579660 [Epub 2007/06/21] (Pubitemid 47312798)
73. R. Jofre, P. Rodriguez-Benitez, J.M. Lopez-Gomez, and R. Perez-Garcia Inflammatory syndrome in patients on hemodialysis J Am Soc Nephrol 17 December (12 Suppl. 3) 2006 S274 S280 PubMed PMID: 17130274 [Epub 2006/11/30]
74. N.D. Vaziri, F. Oveisi, and Y. Ding Role of increased oxygen free radical activity in the pathogenesis of uremic hypertension Kidney Int 53 June (6) 1998 1748 1754 PubMed PMID: 9607208 [Epub 1998/06/02] (Pubitemid 28243760)
75. V. Menon, T. Greene, X. Wang, A.A. Pereira, S.M. Marcovina, and G.J. Beck et al. C-reactive protein and albumin as predictors of all-cause and cardiovascular mortality in chronic kidney disease Kidney Int 68 August (2) 2005 766 772 PubMed PMID: 16014054 [Epub 2005/07/15] (Pubitemid 43323132)
76. R. Wever, P. Boer, M. Hijmering, E. Stroes, M. Verhaar, and J. Kastelein et al. Nitric oxide production is reduced in patients with chronic renal failure Arterioscler Thromb Vasc Biol 19 May (5) 1999 1168 1172 PubMed PMID: 10323766 [Epub 1999/05/14] (Pubitemid 29227634)
77. J. Passauer, F. Pistrosch, E. Bussemaker, G. Lassig, K. Herbrig, and P. Gross Reduced agonist-induced endothelium-dependent vasodilation in uremia is attributable to an impairment of vascular nitric oxide J Am Soc Nephrol 16 April (4) 2005 959 965 PubMed PMID: 15728785 [Epub 2005/02/25] (Pubitemid 41710306)
78. C. Zoccali, S. Bode-Boger, F. Mallamaci, F. Benedetto, G. Tripepi, and L. Malatino et al. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study Lancet 358 December (9299) 2001 2113 2117 PubMed PMID: 11784625 [Epub 2002/01/11] (Pubitemid 34094901)
79. P. Ravani, G. Tripepi, F. Malberti, S. Testa, F. Mallamaci, and C. Zoccali Asymmetrical dimethylarginine predicts progression to dialysis and death in patients with chronic kidney disease: a competing risks modeling approach J Am Soc Nephrol 16 August (8) 2005 2449 2455 PubMed PMID: 15944335 [Epub 2005/06/10] (Pubitemid 41725063)
80. U. Schwarz, M. Buzello, E. Ritz, G. Stein, G. Raabe, and G. Wiest et al. Morphology of coronary atherosclerotic lesions in patients with end-stage renal failure Nephrol Dial Transplant 15 February (2) 2000 218 223 PubMed PMID: 10648668 [Epub 2000/01/29] (Pubitemid 30064276)
81. W.Y. Qunibi Reducing the burden of cardiovascular calcification in patients with chronic kidney disease J Am Soc Nephrol 16 November (Suppl. 2) 2005 S95 S102 PubMed PMID: 16251249 [Epub 2005/10/28]
82. D. Russo, G. Palmiero, A.P. De Blasio, M.M. Balletta, and V.E. Andreucci Coronary artery calcification in patients with CRF not undergoing dialysis Am J Kidney Dis 44 December (6) 2004 1024 1030 PubMed PMID: 15558523 [Epub 2004/11/24] (Pubitemid 39556482)
83. M.N. Budisavljevic, D. Cheek, and D.W. Ploth Calciphylaxis in chronic renal failure J Am Soc Nephrol 7 July (7) 1996 978 982 PubMed PMID: 8829111 [Epub 1996/07/01] (Pubitemid 27465959)
84. M. Ketteler, G. Schlieper, and J. Floege Calcification and cardiovascular health: new insights into an old phenomenon Hypertension 47 June (6) 2006 1027 1034 PubMed PMID: 16618842 [Epub 2006/04/19] (Pubitemid 44289155)
85. A. Covic, M. Kanbay, L. Voroneanu, F. Turgut, D.N. Serban, and I.L. Serban et al. Vascular calcification in chronic kidney disease Clin Sci (Lond) 119 August (3) 2010 111 121 PubMed PMID: 20443781 [Epub 2010/05/07]
86. P.S. Parfrey, and R.N. Foley The clinical epidemiology of cardiac disease in chronic renal failure J Am Soc Nephrol 10 July (7) 1999 1606 1615 PubMed PMID: 10405218 [Epub 1999/07/15] (Pubitemid 29297538)
87. United States Rena Data System Mortality and cause of death 2007 www.usrds.org/2007/ref/H-morte-07.pdf
88. R.C. Ozsoy, W.A. van der Steeg, J.J. Kastelein, L. Arisz, and M.G. Koopman Dyslipidaemia as predictor of progressive renal failure and the impact of treatment with atorvastatin Nephrol Dial Transplant 22 June (6) 2007 1578 1586 PubMed PMID: 17347284 (Pubitemid 47073755)
89. S.Y. Park, C.Y. Song, B.C. Kim, H.K. Hong, and H.S. Lee Angiotensin II mediates LDL-induced superoxide generation in mesangial cells Am J Physiol Renal Physiol 285 November (5) 2003 F909 F915 PubMed PMID: 12837686 [Epub 2003/07/03]
90. M. Chmielewski, E. Bryl, L. Marzec, E. Aleksandrowicz, J.M. Witkowski, and B. Rutkowski Expression of scavenger receptor CD36 in chronic renal failure patients Artif Organs 29 August (8) 2005 608 614 PubMed PMID: 16048476 [Epub 2005/07/29] (Pubitemid 41602837)
91. O. Samuelsson, H. Mulec, C. Knight-Gibson, P.O. Attman, B. Kron, and R. Larsson et al. Lipoprotein abnormalities are associated with increased rate of progression of human chronic renal insufficiency Nephrol Dial Transplant 12 September (9) 1997 1908 1915 PubMed PMID: 9306342 [Epub 1997/11/05] (Pubitemid 27379464)
92. T. Takemura, K. Yoshioka, N. Aya, K. Murakami, A. Matumoto, and H. Itakura et al. Apolipoproteins and lipoprotein receptors in glomeruli in human kidney diseases Kidney Int 43 April (4) 1993 918 927 PubMed PMID: 8479130 (Pubitemid 23105228)
93. B.L. Kasiske, M.P. O'Donnell, P.G. Schmitz, Y. Kim, and W.F. Keane Renal injury of diet-induced hypercholesterolemia in rats Kidney Int 37 March (3) 1990 880 891 PubMed PMID: 2313977 [Epub 1990/03/01] (Pubitemid 20089220)
94. S. Vazquez-Perez, P. Aragoncillo, N. de Las Heras, J. Navarro-Cid, E. Cediel, and D. Sanz-Rosa et al. Atorvastatin prevents glomerulosclerosis and renal endothelial dysfunction in hypercholesterolaemic rabbits Nephrol Dial Transplant 16 Suppl. 1 2001 40 44 PubMed PMID: 11369819 [Epub 2001/05/23] (Pubitemid 32492503)
95. B.L. Kasiske, M.P. O'Donnell, M.P. Cleary, and W.F. Keane Treatment of hyperlipidemia reduces glomerular injury in obese Zucker rats Kidney Int 33 March (3) 1988 667 672 PubMed PMID: 3367557 [Epub 1988/03/01] (Pubitemid 18083115)
96. C. Li, S.W. Lim, B.S. Choi, S.H. Lee, J.H. Cha, and I.S. Kim et al. Inhibitory effect of pravastatin on transforming growth factor beta1-inducible gene h3 expression in a rat model of chronic cyclosporine nephropathy Am J Nephrol 25 November-December (6) 2005 611 620 PubMed PMID: 16308546 [Epub 2005/11/26] (Pubitemid 41816056)
97. T. Ota, T. Takamura, H. Ando, E. Nohara, H. Yamashita, and K. Kobayashi Preventive effect of cerivastatin on diabetic nephropathy through suppression of glomerular macrophage recruitment in a rat model Diabetologia 46 June (6) 2003 843 851 PubMed PMID: 12774163 [Epub 2003/05/30] (Pubitemid 36831414)
98. K. Jandeleit-Dahm, Z. Cao, A.J. Cox, D.J. Kelly, R.E. Gilbert, and M.E. Cooper Role of hyperlipidemia in progressive renal disease: focus on diabetic nephropathy Kidney Int 71 July (Suppl.) 1999 S31 S36 PubMed PMID: 10412733 [Epub 1999/07/21]
99. M. Christensen, A.W. Su, R.W. Snyder, A. Greco, J.H. Lipschutz, and M.P. Madaio Simvastatin protection against acute immune-mediated glomerulonephritis in mice Kidney Int 69 February (3) 2006 457 463 PubMed PMID: 16407885 [Epub 2006/01/13] (Pubitemid 43164436)
100. M.S. Zhou, I.H. Schuman, E.A. Jaimes, and L. Raij Renoprotection by statins is linked to a decrease in renal oxidative stress, TGF-beta, and fibronectin with concomitant increase in nitric oxide bioavailability Am J Physiol Renal Physiol 295 July (1) 2008 F53 F59 PubMed PMID: 18463318 [Epub 2008/05/09]
101. E.S. Schaeffner, T. Kurth, G.C. Curhan, R.J. Glynn, K.M. Rexrode, and C. Baigent et al. Cholesterol and the risk of renal dysfunction in apparently healthy men J Am Soc Nephrol 14 August (8) 2003 2084 2091 PubMed PMID: 12874462 (Pubitemid 36909916)
102. M. Manttari, E. Tiula, T. Alikoski, and V. Manninen Effects of hypertension and dyslipidemia on the decline in renal function Hypertension 26 October (4) 1995 670 675 PubMed PMID: 7558229
103. P. Gounari, D. Tousoulis, C. Antoniades, A.M. Kampoli, P. Stougiannos, and N. Papageorgiou et al. Rosuvastatin but not ezetimibe improves endothelial function in patients with heart failure, by mechanisms independent of lipid lowering Int J Cardiol 142 June (1) 2010 87 91 PubMed PMID: 19200613
104. U. Landmesser, F. Bahlmann, M. Mueller, S. Spiekermann, N. Kirchhoff, and S. Schulz et al. Simvastatin versus ezetimibe: pleiotropic and lipid-lowering effects on endothelial function in humans Circulation 111 May (18) 2005 2356 2363 PubMed PMID: 15867181 (Pubitemid 40647072)
105. C. Heeschen, C.W. Hamm, U. Laufs, S. Snapinn, M. Bohm, and H.D. White et al. Withdrawal of statins increases event rates in patients with acute coronary syndromes Circulation 105 March (12) 2002 1446 1452 PubMed PMID: 11914253 (Pubitemid 34263276)
106. C.Y. Wang, P.Y. Liu, and J.K. Liao Pleiotropic effects of statin therapy: molecular mechanisms and clinical results Trends Mol Med 14 January (1) 2008 37 44 PubMed PMID: 18068482 [Epub 2007/12/11]
107. J.K. Liao, M. Seto, and K. Noma Rho kinase (ROCK) inhibitors J Cardiovasc Pharmacol 50 July (1) 2007 17 24 PubMed PMID: 17666911 [Epub 2007/08/02] (Pubitemid 47220442)
108. A.T. Whaley-Connell, E.M. Morris, N. Rehmer, J.C. Yaghoubian, Y. Wei, and M.R. Hayden et al. Albumin activation of NAD(P)H oxidase activity is mediated via Rac1 in proximal tubule cells Am J Nephrol 27 1 2007 15 23 PubMed PMID: 17204833 [Epub 2007/01/06] (Pubitemid 46364536)
109. S. Wolfrum, K.S. Jensen, and J.K. Liao Endothelium-dependent effects of statins Arterioscler Thromb Vasc Biol 23 May (5) 2003 729 736 PubMed PMID: 12615672 (Pubitemid 36566160)
110. A.S. Antonopoulos, M. Margaritis, R. Lee, K. Channon, and C. Antoniades Statins as anti-inflammatory agents in atherogenesis: molecular mechanisms and lessons from the recent clinical trials Curr Pharm Des 18 11 2012 1519 1530 PubMed PMID: 22364136. Pubmed Central PMCID: 3394171
111. J. Davignon Pleiotropic effects of pitavastatin Br J Clin Pharmacol 73 April (4) 2012 518 535 PubMed PMID: 22053916. Pubmed Central PMCID: 3376429
112. C.G. Mihos, A.M. Pineda, and O. Santana Cardiovascular effects of statins, beyond lipid-lowering properties Pharmacol Res 2014 PubMed PMID: 24631782
113. C.R. Sirtori The pharmacology of statins Pharmacol Res 2014 PubMed PMID: 24657242
114. W. Dichtl, J. Dulak, M. Frick, H.F. Alber, S.P. Schwarzacher, and M.P. Ares et al. HMG-CoA reductase inhibitors regulate inflammatory transcription factors in human endothelial and vascular smooth muscle cells Arterioscler Thromb Vasc Biol 23 January (1) 2003 58 63 PubMed PMID: 12524225 (Pubitemid 36091626)
115. K. Suzumura, K. Tanaka, M. Yasuhara, and H. Narita Inhibitory effects of fluvastatin and its metabolites on hydrogen peroxide-induced oxidative destruction of hemin and low-density lipoprotein Biol Pharm Bull 23 July (7) 2000 873 878 PubMed PMID: 10919369 [Epub 2000/08/05] (Pubitemid 30484388)
116. F. Gueler, J.K. Park, S. Rong, T. Kirsch, C. Lindschau, and W. Zheng et al. Statins attenuate ischemia-reperfusion injury by inducing heme oxygenase-1 in infiltrating macrophages Am J Pathol 170 April (4) 2007 1192 1199 PubMed PMID: 17392159 [Epub 2007/03/30] (Pubitemid 47339327)
117. B. Kwak, F. Mulhaupt, S. Myit, and F. Mach Statins as a newly recognized type of immunomodulator Nat Med 6 December (12) 2000 1399 1402 PubMed PMID: 11100127 [Epub 2000/12/02] (Pubitemid 32001026)
118. T.M. Lu, Y.A. Ding, H.B. Leu, W.H. Yin, W.H. Sheu, and K.M. Chu Effect of rosuvastatin on plasma levels of asymmetric dimethylarginine in patients with hypercholesterolemia Am J Cardiol 94 July (2) 2004 157 161 PubMed PMID: 15246890 (Pubitemid 38902861)
119. C. Antoniades, M. Demosthenous, D. Tousoulis, A.S. Antonopoulos, C. Vlachopoulos, and M. Toutouza et al. Role of asymmetrical dimethylarginine in inflammation-induced endothelial dysfunction in human atherosclerosis Hypertension 58 July (1) 2011 93 98 PubMed PMID: 21518967 [Epub 2011/04/27]
120. O. Hernandez-Perera, D. Perez-Sala, E. Soria, and S. Lamas Involvement of Rho GTPases in the transcriptional inhibition of preproendothelin-1 gene expression by simvastatin in vascular endothelial cells Circ Res 87 September (7) 2000 616 622 PubMed PMID: 11009568 [Epub 2000/09/29]
121. T. Ichiki, K. Takeda, T. Tokunou, N. Iino, K. Egashira, and H. Shimokawa et al. Downregulation of angiotensin II type 1 receptor by hydrophobic 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in vascular smooth muscle cells Arterioscler Thromb Vasc Biol 21 December (12) 2001 1896 1901 PubMed PMID: 11742861 [Epub 2001/12/18] (Pubitemid 34219738)
122. D.H. Walter, S. Dimmeler, and A.M. Zeiher Effects of statins on endothelium and endothelial progenitor cell recruitment Semin Vasc Med 4 November (4) 2004 385 393 PubMed PMID: 15861319 [Epub 2005/04/30] (Pubitemid 40577827)
123. B.A. Mosheimer, N.C. Kaneider, C. Feistritzer, A. Djanani, D.H. Sturn, and J.R. Patsch et al. CD40-ligand-dependent induction of COX-2 gene expression in endothelial cells by activated platelets: inhibitory effects of atorvastatin Blood Coagul Fibrinolysis 16 March (2) 2005 105 110 PubMed PMID: 15741797 (Pubitemid 40418588)
124. R.S. Rosenson, and A.S. Brown Statin use in acute coronary syndromes: cellular mechanisms and clinical evidence Curr Opin Lipidol 13 December (6) 2002 625 630 PubMed PMID: 12441886 (Pubitemid 36009201)
125. S. Shibata, M. Nagase, and T. Fujita Fluvastatin ameliorates podocyte injury in proteinuric rats via modulation of excessive Rho signaling J Am Soc Nephrol 17 March (3) 2006 754 764 PubMed PMID: 16452496 [Epub 2006/02/03]
126. F.C. Cormack-Aboud, P.T. Brinkkoetter, J.W. Pippin, S.J. Shankland, and R.V. Durvasula Rosuvastatin protects against podocyte apoptosis in vitro Nephrol Dial Transplant 2008 PubMed PMID: 18820279 [Epub 2008/09/30]
127. E.P. Heymann, T.I. Kassimatis, and D.J. Goldsmith Dyslipidemia, statins, and CKD patients' outcomes - review of the evidence in the post-sharp era J Nephrol 25 July-August (4) 2012 460 472 PubMed PMID: 22641572 [Epub 2012/05/30]
128. M. Jenkins, and D. Goldsmith Statins and kidney disease: is the study of heart and renal protection at the cutting edge of evidence? Curr Opin Cardiol 27 July (4) 2012 429 440 PubMed PMID: 22678410
129. R. Collins, J. Armitage, S. Parish, P. Sleigh, and R. Peto MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial Lancet 361 June (9374) 2003 2005 2016 PubMed PMID: 12814710 [Epub 2003/06/20]
130. M.J. Koren, M.H. Davidson, D.J. Wilson, R.S. Fayyad, A. Zuckerman, and D.P. Reed et al. Focused atorvastatin therapy in managed-care patients with coronary heart disease and CKD Am J Kidney Dis 53 May (5) 2009 741 750 PubMed PMID: 19216014
131. V.G. Athyros, D.P. Mikhailidis, A.A. Papageorgiou, A.N. Symeonidis, A.N. Pehlivanidis, and V.I. Bouloukos et al. The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study J Clin Pathol 57 July (7) 2004 728 734 PubMed PMID: 15220366 [Epub 2004/06/29] (Pubitemid 38901488)
132. K. Kimura, H. Shimano, K. Yokote, M. Urashima, and T. Teramoto Effects of pitavastatin (LIVALO tablet) on the estimated glomerular filtration rate (eGFR) in hypercholesterolemic patients with chronic kidney disease. Sub-analysis of the LIVALO Effectiveness and Safety (LIVES) Study J Atheroscler Thromb 17 June (6) 2010 601 609 PubMed PMID: 20460830 [Epub 2010/05/13]
133. H.M. Colhoun, D.J. Betteridge, P.N. Durrington, G.A. Hitman, H.A. Neil, and S.J. Livingstone et al. Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS) Am J Kidney Dis 54 November (5) 2009 810 819 PubMed PMID: 19540640
134. J. Shepherd, J.J. Kastelein, V. Bittner, P. Deedwania, A. Breazna, and S. Dobson et al. Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the Treating to New Targets (TNT) study Clin J Am Soc Nephrol 2 November (6) 2007 1131 1139 PubMed PMID: 17942759 [Epub 2007/10/19]
135. J. Atthobari, A.H. Brantsma, R.T. Gansevoort, S.T. Visser, F.W. Asselbergs, and W.H. van Gilst et al. The effect of statins on urinary albumin excretion and glomerular filtration rate: results from both a randomized clinical trial and an observational cohort study Nephrol Dial Transplant 21 November (11) 2006 3106 3114 PubMed PMID: 16720593 [Epub 2006/05/25] (Pubitemid 44567081)
136. M. Rahman, C. Baimbridge, B.R. Davis, J. Barzilay, J.N. Basile, and M.A. Henriquez et al. Progression of kidney disease in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin versus usual care: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Am J Kidney Dis 52 September (3) 2008 412 424 PubMed PMID: 18676075 [Epub 2008/08/05]
137. P.M. Ridker, J. MacFadyen, M. Cressman, and R.J. Glynn Efficacy of rosuvastatin among men and women with moderate chronic kidney disease and elevated high-sensitivity C-reactive protein: a secondary analysis from the JUPITER (Justification for the Use of Statins in Prevention-an Intervention Trial Evaluating Rosuvastatin) trial J Am Coll Cardiol 55 March (12) 2010 1266 1273 PubMed PMID: 20206456 [Epub 2010/03/09]
138. P. Ruggenenti, A. Perna, M. Tonelli, G. Loriga, N. Motterlini, and N. Rubis et al. Effects of add-on fluvastatin therapy in patients with chronic proteinuric nephropathy on dual renin-angiotensin system blockade: the ESPLANADE trial Clin J Am Soc Nephrol 5 November (11) 2010 1928 1938 PubMed PMID: 20671225. Pubmed Central PMCID: 3001777
139. D. Keller Atorvastatin beats rosuvastatin in protecting kidneys in diabetic and nondiabetic patients XLVII European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) Congress, Presented June 27, 2010 Medscape Medical News 2010
140. C. Baigent, M.J. Landray, C. Reith, J. Emberson, D.C. Wheeler, and C. Tomson et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial Lancet 377 June (9784) 2011 2181 2192 PubMed PMID: 21663949 [Epub 2011/06/15]
141. R. Haynes, D. Lewis, J. Emberson, C. Reith, L. Agodoa, and A. Cass et al. Effects of lowering LDL cholesterol on progression of kidney disease J Am Soc Nephrol 2014 PubMed PMID: 24790178
142. L.F. Fried, T.J. Orchard, and B.L. Kasiske Effect of lipid reduction on the progression of renal disease: a meta-analysis Kidney Int 59 January (1) 2001 260 269 PubMed PMID: 11135079 (Pubitemid 32055234)
143. S. Sandhu, N. Wiebe, L.F. Fried, and M. Tonelli Statins for improving renal outcomes: a meta-analysis J Am Soc Nephrol 17 July (7) 2006 2006 2016 PubMed PMID: 16762986 (Pubitemid 44036185)
144. K. Douglas, P.G. O'Malley, and J.L. Jackson Meta-analysis: the effect of statins on albuminuria Ann Intern Med 145 July (2) 2006 117 124 PubMed PMID: 16847294 (Pubitemid 46780585)
145. S.C. Palmer, J.C. Craig, S.D. Navaneethan, M. Tonelli, F. Pellegrini, and G.F. Strippoli Benefits and harms of statin therapy for persons with chronic kidney disease: a systematic review and meta-analysis Ann Intern Med 157 August (4) 2012 263 275 PubMed PMID: 22910937. Pubmed Central PMCID: 3955032
146. S.D. Navaneethan, F. Pansini, V. Perkovic, C. Manno, F. Pellegrini, and D.W. Johnson et al. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis Cochrane Database Syst Rev 2 2009 CD007784 PubMed PMID: 19370693 [Epub 2009/04/17]
147. A. Upadhyay, A. Earley, J.L. Lamont, S. Haynes, C. Wanner, and E.M. Balk Lipid-lowering therapy in persons with chronic kidney disease: a systematic review and meta-analysis Ann Intern Med 157 August (4) 2012 251 262 PubMed PMID: 22910936
148. W. Hou, J. Lv, V. Perkovic, L. Yang, N. Zhao, and M.J. Jardine et al. Effect of statin therapy on cardiovascular and renal outcomes in patients with chronic kidney disease: a systematic review and meta-analysis Eur Heart J 34 June (24) 2013 1807 1817 PubMed PMID: 23470492
149. M. Tonelli, L. Moye, F.M. Sacks, B. Kiberd, and G. Curhan Pravastatin for secondary prevention of cardiovascular events in persons with mild chronic renal insufficiency Ann Intern Med 138 January (2) 2003 98 104 PubMed PMID: 12529091 (Pubitemid 36222496)
150. M. Tonelli, C. Isles, G.C. Curhan, A. Tonkin, M.A. Pfeffer, and J. Shepherd et al. Effect of pravastatin on cardiovascular events in people with chronic kidney disease Circulation 110 September (12) 2004 1557 1563 PubMed PMID: 15364796 [Epub 2004/09/15] (Pubitemid 39297976)
151. J. Shepherd, J.J. Kastelein, V. Bittner, P. Deedwania, A. Breazna, and S. Dobson et al. Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study J Am Coll Cardiol 51 April (15) 2008 1448 1454 PubMed PMID: 18402899 [Epub 2008/04/12] (Pubitemid 351471787)
152. F.W. Asselbergs, G.F. Diercks, H.L. Hillege, A.J. van Boven, W.M. Janssen, and A.A. Voors et al. Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria Circulation 110 November (18) 2004 2809 2816 PubMed PMID: 15492322 (Pubitemid 39473602)
153. C. Wanner, V. Krane, W. Marz, M. Olschewski, J.F. Mann, and G. Ruf et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis N Engl J Med 353 July (3) 2005 238 248 PubMed PMID: 16034009 (Pubitemid 41058323)
154. B.C. Fellstrom, A.G. Jardine, R.E. Schmieder, H. Holdaas, K. Bannister, and J. Beutler et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis N Engl J Med 360 April (14) 2009 1395 1407 PubMed PMID: 19332456 [Epub 2009/04/01]
155. G.F. Strippoli, and J.C. Craig Sunset for statins after AURORA? N Engl J Med 360 April (14) 2009 1455 1457 PubMed PMID: 19332454 [Epub 2009/04/01]
156. T.I. Kassimatis, and P.A. Konstantinopoulos Rosuvastatin in patients undergoing hemodialysis N Engl J Med 361 July (1) 2009 93 author reply 4-5. PubMed PMID: 19579277 [Epub 2009/07/07]
157. K.K. Stevens, and A.G. Jardine SHARP: a stab in the right direction in chronic kidney disease Lancet 377 June (9784) 2011 2153 2154 PubMed PMID: 21663950 [Epub 2011/06/15]
158. S.C. Palmer, S.D. Navaneethan, J.C. Craig, D.W. Johnson, V. Perkovic, and S.U. Nigwekar et al. HMG CoA reductase inhibitors (statins) for dialysis patients Cochrane Database Syst Rev 9 2013 CD004289 PubMed PMID: 24022428
159. M. Barylski, S. Nikfar, D.P. Mikhailidis, P.P. Toth, P. Salari, and K.K. Ray et al. Statins decrease all-cause mortality only in CKD patients not requiring dialysis therapy - a meta-analysis of 11 randomized controlled trials involving 21,295 participants Pharmacol Res 72 June 2013 35 44 PubMed PMID: 23542730
160. V. Tsimihodimos, E. Dounousi, and K.C. Siamopoulos Dyslipidemia in chronic kidney disease: an approach to pathogenesis and treatment Am J Nephrol 28 6 2008 958 973 PubMed PMID: 18612199 [Epub 2008/07/10]
161. I.B. Castello Hyperlipidemia: a risk factor for chronic allograft dysfunction Kidney Int 80 May (Suppl.) 2002 73 77 PubMed PMID: 11982817
162. H. Holdaas, B. Fellstrom, A.G. Jardine, I. Holme, G. Nyberg, and P. Fauchald et al. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial Lancet 361 June (9374) 2003 2024 2031 PubMed PMID: 12814712 [Epub 2003/06/20] (Pubitemid 36695044)
163. B. Fellstrom, H. Holdaas, A.G. Jardine, I. Holme, G. Nyberg, and P. Fauchald et al. Effect of fluvastatin on renal end points in the Assessment of Lescol in Renal Transplant (ALERT) trial Kidney Int 66 October (4) 2004 1549 1555 PubMed PMID: 15458450 (Pubitemid 39298389)
164. N. Younas, C.M. Wu, R. Shapiro, J. McCauley, J. Johnston, and H. Tan et al. HMG-CoA reductase inhibitors in kidney transplant recipients receiving tacrolimus: statins not associated with improved patient or graft survival BMC Nephrol 11 2010 5 PubMed PMID: 20359353. Pubmed Central PMCID: 2855559
165. J.M. McKenney, M.H. Davidson, T.A. Jacobson, J.R. Guyton, and National Lipid Association Statin Safety Assessment Task F Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force Am J Cardiol 97 April (8A) 2006 89C 94C PubMed PMID: 16581336
166. Group MBHPSC, J. Armitage, L. Bowman, R. Collins, S. Parish, and J. Tobert Effects of simvastatin 40 mg daily on muscle and liver adverse effects in a 5-year randomized placebo-controlled trial in 20,536 high-risk people BMC Clin Pharmacol 9 2009 6 PubMed PMID: 19442259. Pubmed Central PMCID: 2676245
167. A. Corsini, and S. Bellosta Drug-drug interaction with statins Expert Rev Clin Pharmacol 1 January (1) 2008 105 113 PubMed PMID: 24410514
168. P.M. Ridker, E. Danielson, F.A. Fonseca, J. Genest, A.M. Gotto Jr., and J.J. Kastelein et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein N Engl J Med 359 November (21) 2008 2195 2207 PubMed PMID: 18997196 [Epub 2008/11/11]
169. N. Sattar, D. Preiss, H.M. Murray, P. Welsh, B.M. Buckley, and A.J. de Craen et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials Lancet 375 February (9716) 2010 735 742 PubMed PMID: 20167359
170. D. Preiss, S.R. Seshasai, P. Welsh, S.A. Murphy, J.E. Ho, and D.D. Waters et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis JAMA 305 June (24) 2011 2556 2564 PubMed PMID: 21693744